(Q47586113)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Claire M Rice

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Alan Whone

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Neil Scolding

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

E A Mallam

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

P Walsh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

N Kane

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

S R Butler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

D I Marks

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

5 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

679-685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Remyelination of the spinal cord following intravenous delivery of bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Human mesenchymal stem cells signals regulate neural stem cell fate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Oligodendrogenesis of adult neural progenitors: differential effects of ciliary neurotrophic factor and mesenchymal stem cell derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

MSCs guide neurite directional extension and promote oligodendrogenesis in NSCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Development of mesenchymal stem cells partially originate from the neural crest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Ontogeny and multipotency of neural crest-derived stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Trophic activity derived from bone marrow mononuclear cells increases peripheral nerve regeneration by acting on both neuronal and glial cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

"Small stem cells" in adult tissues: very small embryonic-like stem cells stand up!

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Comparison of different adult stem cell types for treatment of myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

High passage number of stem cells adversely affects stem cell activation and myocardial protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Stem cells: biologics for regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

The clinical role of evoked potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Multiple sclerosis trial designs for the 21st century: building on recent lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.44

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20445531%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference